Three Nasdaq Stocks to Watch

 |  Includes: MDGL, PARL, TXRH
by: Jim Van Meerten

Here are three NASDAQ stocks that hit their most frequent new highs on Barchart. Try these for your watch list.

Parlux Fragrances (NASDAQ:PARL) - A manufacturer and international distributor of prestige products. It holds licenses for Paris Hilton fragrances, watches, cosmetics, sunglasses, handbags and other small leather accessories in addition to licenses to manufacture and distribute the designer fragrance brands of Perry Ellis, XOXO, Ocean Pacific, Maria Sharapova, Andy Roddick, BabyGund, and Fred Hayman Beverly Hills.

Paris Hilton? That's hot!

  • 96% Barchart technical buy signal
  • 18 new highs in the last month
  • Up 11.63% in the last month
  • Relative Strength Index 70.60% and rising
  • Trading around 2.80 which is above it's 50-day moving average of 2.66
Texas Roadhouse (NASDAQ:TXRH) - A growing, moderately priced, full service restaurant chain. They offer an assortment of specially seasoned and aged steaks hand-cut daily in every restaurant and cooked to order over open gas-fired grills. They also offer their customers, whom they call their guests, a selection of ribs, fish, chicken and vegetable plates, an assortment of hamburgers, salads and sandwiches.
  • 96% Barchart technical buy signal
  • 16 new highs in the last month
  • Up 12.97% in the last month
  • Relative Strength Index 81.99% and rising
  • Trading around 18.20 which is above its 50-day moving average of 15.88
Synta Pharmaceuticals (SNTA) - A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical - and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using compound library and drug discovery capabilities. Synta has a partnership with GlaxoSmithKline (NYSE:GSK) for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma.
  • 100% Barchart technical buy signal
  • 16 new highs in the last month
  • Up 49.58% in the last month
  • Relative Strength Index 87.53
  • Trading around 5.35 which is above its 50 day moving average of 3.95

Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in PARL, TXRH, SNTA over the next 72 hours.